Marshall Wace North America’s Medicines Co MDCO Stock Holding History

Marshall Wace North America’s Portfolio MDCO Stock Details MDCO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-661,541	Closed	-$56.2M	–	1766
2019 Q4	$56.2M	Buy	661,541 +657,376	+15,783%	+$43.8M	0.27%	104
2019 Q3	$208K	Buy	+4,165	New	+$166K	﹤0.01%	958
2019 Q2	–	Sell	-67,884	Closed	-$1.9M	–	1847
2019 Q1	$1.9M	Buy	+67,884	New	+$1.6M	0.01%	525
2018 Q2	–	Sell	-164,878	Closed	-$5.43M	–	1874
2018 Q1	$5.43M	Sell	164,878 -430,116	-72%	-$13.4M	0.03%	551
2017 Q4	$16.3M	Buy	594,994 +424,061	+248%	+$13.1M	0.09%	268
2017 Q3	$6.33M	Buy	170,933 +32,289	+23%	+$1.19M	0.04%	481
2017 Q2	$5.27M	Buy	+138,644	New	+$6.17M	0.04%	484

Other funds holding MDCO

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Marshall Wace North America's MDCO Position: Q1 2020 in Review

Marshall Wace North America sold out of Medicines Co (MDCO) in Q1 2020, closing a stake of 661,541 shares — an estimated $56.2M sold.

Marshall Wace North America first reported a position in MDCO in Q2 2017 and held it in 7 quarters. The position peaked at $56.2M in Q4 2019. 1 fund tracked by Wall St. Rank holds MDCO as of Q1 2020.

Marshall Wace North America reported no remaining Medicines Co position as of Q1 2020 after selling out during the quarter.
Marshall Wace North America sold 661,541 Medicines Co shares in Q1 2020, an estimated $56.2M.
Marshall Wace North America first reported a position in Medicines Co in Q2 2017 and held it in 7 quarters.
Marshall Wace North America's Medicines Co position peaked at $56.2M in Q4 2019.
1 fund tracked by Wall St. Rank held Medicines Co as of Q1 2020.

Based on Marshall Wace North America's 13F filing for Q1 2020, filed 15 May 2020.